Plain-English translation of NCT07317934 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new treatment called LX102, which is delivered as a single injection directly into the back of the eye. Researchers want to see if this gene therapy can help preserve vision in people with a type of age-related macular degeneration (nAMD) — a condition where abnormal blood vessels grow under the macula, the part of the eye responsible for detailed vision. The medication is being compared to , a standard eye injection treatment that you may have already used.
Current treatments for this condition require frequent injections into the eye over time. This trial is testing whether a single injection of the new treatment could provide longer-lasting benefits, potentially reducing the burden of repeated visits and injections while protecting your vision.
You likely qualify if…
You likely don't qualify if…
You will receive a single injection of the medication into the back of your eye. After that, you will return for follow-up visits to check your vision and monitor how well the treatment is working, with the main assessments happening around weeks 40 and 48. The study will compare your vision outcomes with those of participants who receive the standard treatment during the same timeframe.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China